Autoimmune Diseases  >>  Jakafi (ruxolitinib)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Jakafi (ruxolitinib) / Incyte
NCT00550043: A Study Exploring the Safety, Tolerability and Efficacy of a 4 Week Course of INCB018424 in Subjects With Active Rheumatoid Arthritis

Completed
2
50
US, Europe
INCB018424, Placebo
Incyte Corporation
Rheumatoid Arthritis
09/08
09/08

Download Options